Work

MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC

Year: 2023

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.152

Authors: S. Gadgeel, P.A. Jänne, A.I. Spira, S.-H.I. Ou, R.S. Heist, J.M. Pacheco, M.L. Johnson, J.K. Sabari, K. Leventakos, J.A. Mason, K. Velastegui, X. Yan, R. Chao, G.J. Riely

Institutions: Henry Ford Health, Dana-Farber Cancer Institute, Virginia Cancer Specialists, The US Oncology Network, University of California, Irvine, Massachusetts General Hospital, University of Colorado Anschutz, Tennessee Oncology, Mayo Clinic, Mirati Therapeutics (United States), Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045122

Cites:

Cited by: 13

Related to: 10